Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mucositis - todos los demás productos terapéuticos - kepivance está indicado para disminuir la incidencia, duración y severidad de la mucositis oral en pacientes adultos con neoplasias hematológicas recibir radiochemotherapy mieloablativo asociado a una alta incidencia de mucositis severo y que requieren apoyo autólogo-hematopoyéticas-células madre.

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - inmunosupresores - la artritis reumatoide (ar)kineret está indicado en adultos para el tratamiento de los signos y síntomas de la ar en combinación con metotrexato, con una respuesta inadecuada a metotrexato solo. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret debe administrarse en combinación con colchicina, si es apropiado. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hemofilia b - la vitamina k y otros hemostáticos, los factores de la coagulación de la sangre - tratamiento y profilaxis de hemorragias en pacientes con hemofilia b (deficiencia congénita de factor ix).

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenia - antihemorrágicos - doptelet está indicado para el tratamiento de la trombocitopenia severa en pacientes adultos con enfermedad hepática crónica que está programado para someterse a un procedimiento invasivo. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. corticosteroides, inmunoglobulinas).

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - efmoroctocog alfa - hemofilia a - antihemorrágicos - tratamiento y profilaxis de hemorragias en pacientes con hemofilia a (deficiencia congénita de factor viii). elocta puede ser utilizado para todos los grupos de edad.

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agentes antineoplásicos - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab - colagenasa clostridium histolyticum - contrato dupuytren - otras drogas para trastornos del sistema musculoesquelético - , the treatment of dupuytren’s contracture in adult patients with a palpable cord. el tratamiento de hombres adultos con la enfermedad de peyronie con una palpable de la placa y de la curvatura de la deformidad de al menos 30 grados al inicio de la terapia.

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum international ab - nitisinona - tirosinemias - otros tracto alimentario y metabolismo de los productos, - hereditary tyrosinemia type 1 (ht 1)orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht 1) in combination with dietary restriction of tyrosine and phenylalanine. alkaptonuria (aku)orfadin is indicated for the treatment of adult patients with alkaptonuria (aku).

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxística - inmunosupresores - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.